Cargando…

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

Secondary hyperparathyroidism (SHPT), a very frequent, severe, and worsening complication of chronic kidney disease, is characterized by high serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism. Clinically, SHPT shows renal osteodystrophy, vascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cozzolino, Mario, Galassi, Andrea, Conte, Ferruccio, Mangano, Michela, Di Lullo, Luca, Bellasi, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461056/ https://www.ncbi.nlm.nih.gov/pubmed/28615947 http://dx.doi.org/10.2147/TCRM.S108490

Ejemplares similares

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
por: Bellasi, Antonio, et al.
Publicado: (2019)

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066
por: Russo, Domenico, et al.
Publicado: (2020)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Cardiovascular disease in dialysis patients
por: Cozzolino, Mario, et al.
Publicado: (2018)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

The ideal marker for measuring GFR: what are we looking for?
por: Claudio, Maioli, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2023)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
por: Dachy, Guillaume, et al.
Publicado: (2021)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Which Vitamin D in CKD-MBD? The Time of Burning Questions
por: Galassi, Andrea, et al.
Publicado: (2013)

Effects of a medium cut-off (Theranova(®)) dialyser on haemodialysis patients: a prospective, cross-over study
por: Cozzolino, Mario, et al.
Publicado: (2019)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy
por: Frittoli, Michela, et al.
Publicado: (2022)

Chronic Kidney Disease: The Silent Epidemy
por: Bellasi, Antonio, et al.
Publicado: (2019)

Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients
por: Bellasi, Antonio, et al.
Publicado: (2021)

Correction of metabolic acidosis improves insulin resistance in chronic kidney disease
por: Bellasi, Antonio, et al.
Publicado: (2016)

Nutritional secondary hyperparathyroidism in two ponies
por: Lacitignola, Luca, et al.
Publicado: (2018)

Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients
por: Bellasi, Antonio, et al.
Publicado: (2021)

Vitamin K in Chronic Kidney Disease
por: Cozzolino, Mario, et al.
Publicado: (2019)

Cinacalcet: the chemical parathyroidectomy?
por: Bellasi, Antonio, et al.
Publicado: (2013)

Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights
por: Di Micco, Lucia, et al.
Publicado: (2019)

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study
por: Roggeri, Daniela Paola, et al.
Publicado: (2014)

COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis?
por: Cozzolino, Mario, et al.
Publicado: (2021)

The Key Role of Phosphate on Vascular Calcification
por: Cozzolino, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_37jgs1bdt643hdg3s5ci6um9oj